Tagged with BMS

Sweden Iddo Leshem, general manager Nordics at Bristol-Myers Squibb (BMS), talks about the uniqueness of Sweden’s collaborative culture and shatters some of the entrenched stereotypes about the country. He then breaks down the drivers behind the outstanding performance of the affiliate and emphasizes the important role Sweden plays in the development…

Thailand PharmaBoardroom last reported on Thailand in 2015, meeting country managers from across the healthcare and life sciences value chain. Here, we chart some of their career progressions since then.   Sticking with Servier Guillaume Drianno Guillaume Drianno was Thailand country manager for French firm Servier between 2013 and 2017. Prior…

Sweden The top 50 most sold drugs in Sweden for 2018. AbbVie’s Humira takes the top spot for the second year running, followed by Gilead’s Epclusa and BMS and Pfizer’s Eliquis.   Made with Visme Infographic Maker  

Turkey Ece Kaşıkçı, General Manager, Bristol-Myers Squibb (BMS) Turkey, outlines how BMS’ groundbreaking immuno-oncology therapy has proudly become the first product of its kind to be registered and reimbursed in the country. She also highlights the company’s collaborative approach to reach this remarkable milestone. Ece also discusses her vision for BMS…

Brazil Gaetano Crupi, president and general manager of BMS in Brazil, leverages his long-standing experience at the head of prestigious pharmaceutical companies’ affiliates to provide an insightful overview of the key success factors to consider in the Brazilian market. He also documents BMS’ commitment to being a frontrunner in the medical,…

Colombia Sandra Ramirez, General Manager of Bristol-Myers Squibb Colombia & Mexico, reveals valuable insights into the long-standing presence of BMS in Colombia, marked by a continuous dedication to increase access to medicine, the gradual development of their immuno-oncology pipeline and the creation of an inclusive culture formed by satisfied employees. Ms.…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…

France Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this field, with a number of companies, institutes and hospitals pioneering new forms of treatment and adapting policy to fit the…

Ireland Noel Heaney, general manager of BMS Biologics Ireland, provides an overview of BMS in Ireland, its exciting new USD 900 million biologics facility in Cruiserath, their innovative HR programs and his five-year-vision for BMS Biologics in Ireland. BMS has a strong heritage in Ireland dating back to 1964 when it…

Pharma The GM of France for Bristol-Myers Squibb (BMS) discusses becoming a “diversified biopharma company”, their commitment to remaining a model of excellence for other affiliates, and his personal philosophy of leadership, moulded by two decades of international experience. You started off your term with a restructuring plan for the French…

Pharma Automation and consolidation have affected pharmaceutical companies worldwide, and Puerto Rico is no exception. The island has benefited from the trend towards lower volume, higher value products which often use the smaller plants Puerto Rico offers. Some companies, like Merck, are transforming their sites from pure manufacturing to commercialization. These trends point to…

Thailand BMS Thailand’s country manager explains the organization’s new business strategy in Thailand under her leadership, Thailand’s potential to become a regional center and why BMS is here to stay.   BMS is actively working towards positioning Thailand as the regional hub due to its strategic location and good talent pool…